Brennan Aoife — SEC Form 4 filings
SEC reporting owner CIK 1714563. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-30.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-06-06 to 2026-06-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 51,520 shares, $432,133 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 30,902 shares @ $13.17 ($406,979) in Climb Bio, Inc., filed 2026-06-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | President and CEO, Director | 5 | — | 2 legs · 51,520 sh · $432,133 | 8 |
| Xilio Therapeutics, Inc. (XLO) | Director | 3 | — | — | 3 |
| FIBROGEN INC (FGEN) | Director | 1 | — | — | 1 |
Form 4 filings — Brennan Aoife
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-30 | 4 | Climb Bio, Inc. (CLYM) | Option exercise (M): 68,750 · Sale (S): 30,902 @ $13.17 · Option exercise (M): 68,750 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Climb Bio, Inc. (CLYM) | Grant/award (A): 700,000 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Climb Bio, Inc. (CLYM) | Option exercise (M): 68,750 · Sale (S): 20,618 @ $1.22 · Option exercise (M): 68,750 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-01-15 | 4 | Climb Bio, Inc. (CLYM) | Grant/award (A): 1,150,000 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Eliem Therapeutics, Inc. (ELYM) | Grant/award (A): 550,000 (derivative) @ $0 · Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | FIBROGEN INC (FGEN) | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1714563 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →